Antidepressants and the risk of suicidal behaviors
- PMID: 15265848
- DOI: 10.1001/jama.292.3.338
Antidepressants and the risk of suicidal behaviors
Abstract
Context: The relation between use of antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and suicidal ideation and behaviors has received considerable public attention recently. The use of such drugs among teenagers has been of particular concern.
Objective: To estimate the relative risks (RRs) of nonfatal suicidal behavior in patients starting treatment with 1 of 3 antidepressant drugs compared with patients starting treatment with dothiepin.
Design and setting: Matched case-control study of patients treated in UK general practices using the UK General Practice Research Database for 1993-1999.
Participants: The base population included 159,810 users of the 4 antidepressant drugs. Participants could have used only 1 of these antidepressants and had to have received at least 1 prescription for the study antidepressant within 90 days before their index date (the date of suicidal behavior or ideation for cases and the same date for matched controls).
Main outcome measures: Frequency of first-time exposure to amitriptyline, fluoxetine, paroxetine, and dothiepin of patients with a recorded diagnosis of first-time nonfatal suicidal behavior or suicide compared with comparable patients who did not exhibit suicidal behavior.
Results: After controlling for age, sex, calendar time, and time from first antidepressant prescription to the onset of suicidal behavior, the relative risks for newly diagnosed nonfatal suicidal behavior in 555 cases and 2062 controls were 0.83 (95% confidence interval, [CI] 0.61-1.13) for amitriptyline, 1.16 (95% CI, 0.90-1.50) for fluoxetine, and 1.29 (95% CI, 0.97-1.70) for paroxetine compared with those using dothiepin. The RR for suicidal behavior among patients first prescribed an antidepressant within 1 to 9 days before their index date was 4.07 (95% CI, 2.89-5.74) compared with patients who were first prescribed an antidepressant 90 days or more before their index date. Time since first antidepressant prescription was not, however, a confounder of the relation between specific antidepressants and suicidal behavior since its relation to suicidal behavior was not materially different among users of the 4 study drugs. Similarly for fatal suicide, the RR among patients who were first prescribed an antidepressant within 1 to 9 days before their index date was 38.0 (95% CI, 6.2-231) compared with those who were first prescribed an antidepressant 90 days or more before their index date. There were no significant associations between the use of a particular study antidepressant and the risk of suicide.
Conclusions: The risk of suicidal behavior after starting antidepressant treatment is similar among users of amitriptyline, fluoxetine, and paroxetine compared with the risk among users of dothiepin. The risk of suicidal behavior is increased in the first month after starting antidepressants, especially during the first 1 to 9 days. A possible small increase in risk (bordering statistical significance) among those starting the newest antidepressant, paroxetine, is of a magnitude that could readily be due to uncontrolled confounding by severity of depression. Based on limited information, we also conclude that there is no substantial difference in effect of the 4 drugs on people aged 10 to 19 years.
Comment in
-
Suicide risk and the SSRIs.JAMA. 2004 Jul 21;292(3):379-81. doi: 10.1001/jama.292.3.379. JAMA. 2004. PMID: 15265855 No abstract available.
-
Antidepressants and the risk of suicidal behaviors.JAMA. 2004 Dec 15;292(23):2833; author reply 2833. doi: 10.1001/jama.292.23.2833-b. JAMA. 2004. PMID: 15598909 No abstract available.
-
Antidepressants and the risk of suicidal behaviors.JAMA. 2004 Dec 15;292(23):2833; author reply 2833. doi: 10.1001/jama.292.23.2833-a. JAMA. 2004. PMID: 15598910 No abstract available.
Similar articles
-
Antidepressants and suicide: a commentary on a significant contribution to this debate.Crisis. 2005;26(2):97-8. doi: 10.1027/0227-5910.26.2.97. Crisis. 2005. PMID: 16138748 No abstract available.
-
Antidepressants and the risk of suicidal behaviors.JAMA. 2004 Dec 15;292(23):2833; author reply 2833. doi: 10.1001/jama.292.23.2833-a. JAMA. 2004. PMID: 15598910 No abstract available.
-
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.Pediatrics. 2010 May;125(5):876-88. doi: 10.1542/peds.2009-2317. Epub 2010 Apr 12. Pediatrics. 2010. PMID: 20385637 Free PMC article.
-
Newer generation antidepressants for depressive disorders in children and adolescents.Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD004851. doi: 10.1002/14651858.CD004851.pub3. Cochrane Database Syst Rev. 2012. PMID: 23152227 Free PMC article. Review.
-
Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004851. doi: 10.1002/14651858.CD004851.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851. doi: 10.1002/14651858.CD004851.pub3 PMID: 17636776 Updated. Review.
Cited by
-
A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.Am J Psychiatry. 2012 Sep;169(9):937-945. doi: 10.1176/appi.ajp.2012.12010009. Am J Psychiatry. 2012. PMID: 22864465 Free PMC article. Clinical Trial.
-
Predictors of start of different antidepressants in patient charts among patients with depression.J Manag Care Spec Pharm. 2015 May;21(5):424-30. doi: 10.18553/jmcp.2015.21.5.424. J Manag Care Spec Pharm. 2015. PMID: 25943003 Free PMC article.
-
Case reports of suspected adverse drug reactions: case reports generate signals efficiently.BMJ. 2006 Feb 25;332(7539):488. doi: 10.1136/bmj.332.7539.488-a. BMJ. 2006. PMID: 16497771 Free PMC article. No abstract available.
-
Antidepressant-induced suicidality: an update.CNS Neurosci Ther. 2010 Aug;16(4):227-34. doi: 10.1111/j.1755-5949.2010.00160.x. Epub 2010 Apr 16. CNS Neurosci Ther. 2010. PMID: 20553304 Free PMC article. Review.
-
Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.BMJ Open. 2018 Oct 8;8(10):e023830. doi: 10.1136/bmjopen-2018-023830. BMJ Open. 2018. PMID: 30297350 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
